Medically reviewed by Huma Sheikh, MD Key Takeaways The medications approved by the Food and Drug Administration (FDA) for ...

Neuroacanthocytosis syndromes comprise a heterogeneous group of rare, genetically defined disorders that are primarily characterised by movement disturbances and the presence of ...

Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

Benign hereditary chorea (BHC) is a rare, autosomal dominant neurological disorder characterised by early-onset, non-progressive chorea. Mutations in the NKX2-1 gene, which encodes the thyroid ...

Credit: Getty Images. Valbenazine 40mg achieved greater placebo-adjusted improvement in chorea as early as week 2 and sustained greater efficacy through week 12 compared with placebo. Valbenazine ...

Our one-year pediatric movement disorders fellowship is designed to prepare child neurologists to become experts in the evaluation and treatment of conditions causing unwanted involuntary movements.

In a study on treatments and outcomes in patients with Sydenham chorea (SC), corticosteroids were associated with faster resolution, while antibiotics, corticosteroids, and sodium valproate were ...